Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 1997

Conditions
Esophageal Cancer
Interventions
DRUG

paclitaxel

Trial Locations (30)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

10461

Albert Einstein Comprehensive Cancer Center, The Bronx

10595

New York Medical College, Valhalla

14621

Rochester General Hospital, Rochester

20422

Veterans Affairs Medical Center - Washington, DC, Washington D.C.

27710

Duke Comprehensive Cancer Center, Durham

29303

Palmetto Hematology/Oncology Associates, Spartanburg

29403

Hollings Cancer Center, Charleston

31405

Savannah Hematology Oncology Associates, Savannah

33901

Florida Cancer Specialists, Fort Myers

36607

Cancer Center of Southern Alabama, Mobile

44309

Akron City Hospital, Akron

46617

Michiana Hematology/Oncology P.C., South Bend

53226

Medical College of Wisconsin, Milwaukee

59802

Missoula Medical Oncology P.C., Missoula

60004

Northwest Medical Specialists, P.C., Arlington Heights

70506

Louisiana Oncology Associates, Lafayette

77024

Oncology Consultants, Houston

78759

Lone Star Oncology, Austin

79106

Harrington Cancer Center, Amarillo

89109

Nevada Cancer Center, Las Vegas

92354

Loma Linda University Medical Center, Loma Linda

94121

Veterans Affairs Medical Center - San Francisco, San Francisco

51101-1733

Siouxland Hematology-Oncology, Sioux City

02215

Beth Israel Deaconess Medical Center, Boston

01605

Memorial Hospital, Worcester

07103

University of Medicine and Dentistry of New Jersey - MOBILE, Newark

27835-6028

Pitt County Memorial Hospital, Greenville

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theradex

INDUSTRY